Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVENUE THERAPEUTICS, INC.

(ATXI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Avenue Therapeutics Shares Drop 28% After FDA Meeting Scheduled

11/29/2021 | 10:36am EST

By Chris Wack

Avenue Therapeutics Inc. shares were up 28% to $1.42 Monday after the U.S. Food and Drug Administration informed the company that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee is tentatively scheduled for Feb. 15, 2022.

The company said the committees will discuss the IV tramadol new drug application.

The FDA previously said that input from an advisory committee is needed for the Office of New Drugs to reach a decision on Avenue's formal dispute resolution request and that the OND will respond to Avenue's appeal within 30 calendar days after the advisory committee meeting.

Volume for the stock was 2.4 million shares at 10:15 a.m. ET, compared with a 65-day average volume of 103,000 shares. The stock hit its 52-week low on Wednesday.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

11-29-21 1036ET

All news about AVENUE THERAPEUTICS, INC.
01/12Cipla Arm to Remain Avenue Therapeutics Shareholder Despite Termination of Acquisition
MT
01/07AVENUE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/07Avenue Therapeutics, Inc. Announces Executive Changes
CI
2021Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending..
CI
2021Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement En..
CI
2021AVENUE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021Avenue Therapeutics Announces Closing of Public Offering of Common Stock
GL
2021Health Care Stocks Finishing Near Intra-Day Highs
MT
2021Health Care Stocks Rising Monday Afternoon
MT
2021AVENUE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
AQ
More news
Analyst Recommendations on AVENUE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020 - - -
Net income 2020 -5,15 M - -
Net cash 2020 3,13 M - -
P/E ratio 2020 -19,1x
Yield 2020 -
Capitalization 14,4 M 14,4 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 4
Free-Float -
Chart AVENUE THERAPEUTICS, INC.
Duration : Period :
Avenue Therapeutics, Inc. Technical Analysis Chart | ATXI | US05360L2051 | MarketScreener
Technical analysis trends AVENUE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,69 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Lucy Lu President, CEO, CFO & Director
Lindsay Allan Rosenwald Executive Chairman
Scott A. Reines Chief Medical Officer
Neil Herskowitz Independent Director
Jay D. Kranzler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AVENUE THERAPEUTICS, INC.-24.01%14
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624